Back to search results

Noninvasive Ultrasound Assessment of Bladder Dysfunction

This study is testing a new ultrasound method called Quantitative Ultrasound Bladder Vibrometry (QUBV) to see how well it can detect abnormal bladder function. This includes conditions like bladder dysfunction, overactive bladder, and enlarged prostate (BPH) with urinary obstruction. The main goal is to see how accurately QUBV can measure bladder pressure. You might be eligible if you are between 18 and 90 years old and are scheduled for a urodynamic study (a test of bladder function) or a specific prostate treatment. The study is currently unclear on its recruitment status.

Study design
This is an observational study, meaning participants will be observed without receiving a specific intervention from the study. It aims to enroll 2023 participants.
What's involved
Participants will have a QUBV ultrasound performed at the same time as their regularly scheduled urodynamic study.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, measuring detrusor pressure, will be assessed up to study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05652023

Noninvasive Ultrasound Assessment of Detrusor Dysfunction

Recruiting
Not specifiedAges 18–90Observational
Mayo Clinic
~2,023 participants
Updated 2026-03-27 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Accuracy of quantitative ultrasound vibrometry for measuring detrusor pressure
Measured over time Frame: Up to study completion, an average of 1 year

Conditions

Bladder Dysfunction
Overactive Bladder
BPH With Urinary Obstruction

Explore related trials

Benign Prostatic HyperplasiaBladder DysfunctionOveractive Bladder

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Azra Alizad, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Azra Alizad, MD
[email protected]
5075381727
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aim1:
Aim2: Inclusions: Age \>45 scheduled to undergo selective photovaporization of the prostate.

Exclusion

Aim1:Obesity (BMI \>35kg/m2), known neurologic disease impacting bladder function (e.g. spinal cord injury, multiple sclerosis, Parkinson's, prior cerebrovascular accident), previous pelvic radiation therapy, previous radical pelvic surgery (such as for uterine or colorectal cancer), prior bladder surgery (including prostate resection), and pregnant or breast-feeding women.
Aim2:Obesity (BMI \>35kg/m2), known neurologic disease impacting bladder function (e.g. spinal cord injury, multiple sclerosis, Parkinson's, prior cerebrovascular accident), previous pelvic radiation therapy, previous radical pelvic surgery (such as colorectal cancer).

What this trial measures

  • Accuracy of quantitative ultrasound vibrometry for measuring detrusor pressuretime Frame: Up to study completion, an average of 1 year

    Will be reported including 95% confidence intervals derived from the cross-validation procedure.